GlassScriptPhysician profile
Colin R Trout
NPI 1821090739
$7,570.32
in general payments reported to CMS, 2019-2025
24 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,026 · 2020: $683 · 2021: $1,141 · 2022: $1,086 · 2023: $710 · 2024: $567 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.93 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,963.79 | 2019-2025 | |
| Janssen Biotech, INC. | $1,025.95 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $1,022.56 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $765.92 | 2019-2025 | Skyrizi |
| Lilly USA, LLC | $447.29 | 2019-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $396.46 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $325.65 | 2019-2023 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $301.81 | 2019-2025 | Libtayo, Dupixent |
| Sanofi-Aventis U.S. LLC | $217.19 | 2019-2022 | |
| Pfizer INC. | $210.23 | 2019-2023 | |
| Ucb, INC. | $192.80 | 2019-2022 | |
| Galderma Laboratories, L.P. | $171.18 | 2021-2025 | Nemluvio |
| Amgen INC. | $79.66 | 2019-2020 | |
| Apyx Medical Corporation | $69.61 | 2019 | |
| Mayne Pharma Commercial LLC | $67.01 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $53.95 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.99 | 2020-2022 | |
| Prugen, INC. Pharmaceuticals | $44.05 | 2019 | |
| Incyte Corporation | $41.88 | 2021-2023 | Opzelura |
| Celgene Corporation | $36.88 | 2019 | |
| Biofrontera INC. | $27.44 | 2021-2022 | |
| Journey Medical Corporation | $22.38 | 2022 | |
| Allergan, INC. | $20.14 | 2020 | |
| Genentech USA, INC. | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Trout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.